Eribulin in combination with bevacizumab as second-line treatment for HER2–negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)
Carmine De Angelis(Baylor College of Medicine), Grazia Arpino(University of Naples Federico II), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Antônio Bernardo(Fondazione Salvatore Maugeri), Teresa Gamucci, Alessandra Fabi(Agostino Gemelli University Polyclinic), Irene De Santo(University of Molise), Valeria Forestieri(University of Naples Federico II), Mario Giuliano(Regione Campania), Lucia Del Mastro(Ospedale Policlinico San Martino), Dario Bruzzese(University of Naples Federico II), Sabino De Placido, Stefania Russo(National Center for Oncological Hadrontherapy), Rossella Lauria, Editta Baldini, Andrea Michelotti(University of Pisa), Francesca Poggio(Ospedale Policlinico San Martino), Luigi Leo, Pietro De Placido(University of Naples Federico II)
Cited by 1
Related Papers
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724